{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:47:55Z","timestamp":1792608475112,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073612"],"award-info":[{"award-number":["82073612"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"crossref","award":["GWV-10.1-XK16"],"award-info":[{"award-number":["GWV-10.1-XK16"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tuberculosis (TB) has a serious impact on people\u2019s health. China is one of 30 countries that has a high TB burden. As the currently decreasing speed of the incidence of TB, the WHO\u2019s goal of \u201cEnd TB Strategy\u201d is hard to achieve by 2035. As a result, a SEIR model that determines the impact of different tuberculosis preventive treatments (TPTs) in different age groups, and the effect of different interventions on latent TB infections (LTBIs) in China is developed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A Susceptible-Exposed-Infectious-Recovered (SEIR) model was established. Goodness-of-fit tests were used to assess model performance. Predictive analysis was used to assess the effect of different interventions on LTBIs and achieving the goals of the \u201cEnd TB Strategy\u201d.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The Chi-square test indicated the model provided a good statistical fit to previous data on the incidence of TB (\u03c7<jats:sup>2<\/jats:sup>\u2009=\u20090.3085, p\u2009&gt;\u20090.999). The 1HP treatment regimen (daily rifapentine\u2009+\u2009isoniazid for 4\u00a0weeks) was most effective in reducing the number of TB cases by 2035. The model indicated that several strategies could achieve the 2035 target of the \u201cEnd TB Strategy\u201d: completion of active case finding (ACF) for LTBI and TPT nation-wide within 5\u00a0years; completion of ACF for LTBIs and TPT within 2\u00a0years in high-incidence areas; completion of TPT in the elderly within 2\u00a0years; or introduction of a new vaccine in which the product of annual doses and vaccine efficiency in the three age groups above 14\u00a0years old reached 10.5\u00a0million.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The incidence of TB in China declined gradually from 2005 to 2019. Implementation of ACF for LTBIs and TPT nation-wide or in areas with high incidence, in the elderly, or administration of a new and effective vaccine could greatly reduce the number of TB cases and achieve the 2035 target of the \u201cEnd TB Strategy\u201d in China.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07465-5","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T13:04:14Z","timestamp":1653311054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effect of different interventions for latent tuberculosis infections in China: a model-based study"],"prefix":"10.1186","volume":"22","author":[{"given":"Zexuan","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4497-5251","authenticated-orcid":false,"given":"Weibing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"key":"7465_CR1","unstructured":"WHO. Global tuberculosis report 2021. Geneva: WHO; 2021. https:\/\/www.who.int\/publications-detail-redirect\/9789240037021."},{"key":"7465_CR2","unstructured":"China Nb. China statistical yearbook 2020. China Statistics Publishing House; 2020."},{"key":"7465_CR3","unstructured":"WHO. WHO|The end TB strategy. Geneva: World Health Organization; 2015. http:\/\/www.who.int\/tb\/strategy\/en\/."},{"key":"7465_CR4","volume-title":"Global tuberculosis report 2020","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. Global tuberculosis report 2020. Geneva: WHO; 2020."},{"issue":"5","key":"7465_CR5","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1183\/09031936.00120908","volume":"33","author":"U Mack","year":"2009","unstructured":"Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J. 2009;33(5):956\u201373.","journal-title":"Eur Respir J"},{"key":"7465_CR6","doi-asserted-by":"crossref","unstructured":"Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000;161(4 Pt 2):S221\u2013247.","DOI":"10.1164\/ajrccm.161.supplement_3.ats600"},{"key":"7465_CR7","unstructured":"WHO consolidated guidelines on tuberculosis. Module 1, Module 1. Geneva: WHO; 2020. Accessed 1 Mar 2021."},{"issue":"03","key":"7465_CR8","first-page":"204","volume":"43","author":"Y He","year":"2021","unstructured":"He Y, Zhang H, Xin H, Gao L. Application of tuberculin skin test and its optimization. Chin J Anti-TB. 2021;43(03):204\u201310.","journal-title":"Chin J Anti-TB"},{"issue":"20","key":"7465_CR9","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1056\/NEJMsa031667","volume":"350","author":"CR Horsburgh","year":"2004","unstructured":"Horsburgh CR. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004;350(20):2060\u20137.","journal-title":"N Engl J Med"},{"issue":"2","key":"7465_CR10","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1016\/S2214-109X(18)30452-2","volume":"7","author":"RC Harris","year":"2019","unstructured":"Harris RC, Sumner T, Knight GM, Evans T, Cardenas V, Chen C, et al. Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study. Lancet Glob Health. 2019;7(2):e209\u201318.","journal-title":"Lancet Glob Health"},{"issue":"33","key":"7465_CR11","doi-asserted-by":"publisher","first-page":"13980","DOI":"10.1073\/pnas.0901720106","volume":"106","author":"LJ Abu-Raddad","year":"2009","unstructured":"Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM, Dye C, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci USA. 2009;106(33):13980\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"43","key":"7465_CR12","doi-asserted-by":"publisher","first-page":"15520","DOI":"10.1073\/pnas.1404386111","volume":"111","author":"GM Knight","year":"2014","unstructured":"Knight GM, Griffiths UK, Sumner T, Laurence YV, Gheorghe A, Vassall A, et al. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc Natl Acad Sci USA. 2014;111(43):15520\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1\u20133","key":"7465_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1472-9792(02)00056-2","volume":"83","author":"C Dye","year":"2003","unstructured":"Dye C, Watt CJ, Bleed DM, Williams BG. What is the limit to case detection under the DOTS strategy for tuberculosis control? Tuberculosis (Edinb). 2003;83(1\u20133):35\u201343.","journal-title":"Tuberculosis (Edinb)"},{"issue":"2","key":"7465_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mbs.2012.02.003","volume":"236","author":"C Ozcaglar","year":"2012","unstructured":"Ozcaglar C, Shabbeer A, Vandenberg SL, Yener B, Bennett KP. Epidemiological models of Mycobacterium tuberculosis complex infections. Math Biosci. 2012;236(2):77\u201396.","journal-title":"Math Biosci"},{"issue":"11","key":"7465_CR15","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","volume":"380","author":"S Swindells","year":"2019","unstructured":"Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019;380(11):1001\u201311.","journal-title":"N Engl J Med"},{"issue":"1","key":"7465_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1005136","volume":"365","author":"NA Martinson","year":"2011","unstructured":"Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365(1):11\u201320.","journal-title":"N Engl J Med"},{"issue":"4","key":"7465_CR17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","volume":"170","author":"D Menzies","year":"2004","unstructured":"Menzies D, Dion M-J, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004;170(4):445\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"7465_CR18","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa1507198","volume":"373","author":"C Danel","year":"2015","unstructured":"TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808\u201322.","journal-title":"N Engl J Med"},{"key":"7465_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12916-016-0589-3","volume":"14","author":"SM Hermans","year":"2016","unstructured":"Hermans SM, Grant AD, Chihota V, Lewis JJ, Vynnycky E, Churchyard GJ, et al. The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study. BMC Med. 2016;14:45.","journal-title":"BMC Med"},{"issue":"23","key":"7465_CR20","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","volume":"365","author":"TR Sterling","year":"2011","unstructured":"Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155\u201366.","journal-title":"N Engl J Med"},{"issue":"1","key":"7465_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/s12879-018-3468-z","volume":"18","author":"YL Schein","year":"2018","unstructured":"Schein YL, Madebo T, Andersen HE, Arnesen TM, Dyrhol-Riise AM, Tveiten H, et al. Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study. BMC Infect Dis. 2018;18(1):587.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"7465_CR22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa1714283","volume":"379","author":"D Menzies","year":"2018","unstructured":"Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440\u201353.","journal-title":"N Engl J Med"},{"issue":"9","key":"7465_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i09","volume":"33","author":"K Soetaert","year":"2010","unstructured":"Soetaert K, Petzoldt T, Setzer RW. Solving differential equations in R: package deSolve. J Stat Softw. 2010;33(9):1\u201325.","journal-title":"J Stat Softw"},{"key":"7465_CR24","unstructured":"Expert consensus on screening and preventive treatment of latent Mycobacterium tuberculosis infection in children. Chin J Tuberc Respir Dis. 2020;43:345\u20139."},{"issue":"8","key":"7465_CR25","doi-asserted-by":"publisher","first-page":"939","DOI":"10.5588\/ijtld.13.0131","volume":"18","author":"W-B Wang","year":"2014","unstructured":"Wang W-B, Zhang H, Petzold M, Zhao Q, Xu B, Zhao G-M. Cost-effectiveness of the Health X Project for tuberculosis control in China. Int J Tuberc Lung Dis. 2014;18(8):939\u201345.","journal-title":"Int J Tuberc Lung Dis"},{"key":"7465_CR26","unstructured":"National tuberculosis control progress in 2009. In: Proceedings of the 2010 National Annual Conference on Tuberculosis Control. Beijing; 2010. p. 2\u201323. https:\/\/d.wanfangdata.com.cn\/conference\/ChZDb25mZXJlbmNlTmV3UzIwMjEwNTIxEgc3NDQ4ODYyGghwbTg2NWc1bg%3D%3D."},{"key":"7465_CR27","unstructured":"General Office of the Chinese Council. General Office of the Chinese Council on the issuance of the national tuberculosis prevention and treatment plan (2011\u20132015). 2011. http:\/\/www.gov.cn\/zwgk\/2011-12\/06\/content_2012869.htm."},{"issue":"25","key":"7465_CR28","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","volume":"381","author":"DR Tait","year":"2019","unstructured":"Tait DR, Hatherill M, Van Der Meeren O, Ginsberg AM, Van Brakel E, Salaun B, et al. Final analysis of a trial of M72\/AS01E vaccine to prevent tuberculosis. N Engl J Med. 2019;381(25):2429\u201339.","journal-title":"N Engl J Med"},{"issue":"10","key":"7465_CR29","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1473-3099(13)70187-7","volume":"13","author":"B Durovni","year":"2013","unstructured":"Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, King BS, et al. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis. 2013;13(10):852\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"7465_CR30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/COH.0000000000000504","volume":"13","author":"B Durovni","year":"2018","unstructured":"Durovni B, Cavalcante S. Preventive therapy for HIV-associated tuberculosis. Curr Opin HIV AIDS. 2018;13(6):507\u201311.","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"7465_CR31","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S1473-3099(19)30625-5","volume":"20","author":"LK Schrager","year":"2020","unstructured":"Schrager LK, Vekemens J, Drager N, Lewinsohn DM, Olesen OF. The status of tuberculosis vaccine development. Lancet Infect Dis. 2020;20(3):e28-37.","journal-title":"Lancet Infect Dis"},{"key":"7465_CR32","first-page":"580","volume":"41","author":"Y Wang","year":"2020","unstructured":"Wang Y, Wang W, Li T, Chen S, Wang Y, Chen W, et al. TB burden prediction under different diagnostic scenarios, a dynamic modeling study. Chin J Epidemiol. 2020;41:580\u20134.","journal-title":"Chin J Epidemiol"},{"issue":"1","key":"7465_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12976-020-00124-9","volume":"17","author":"S Liu","year":"2020","unstructured":"Liu S, Bi Y, Liu Y. Modeling and dynamic analysis of tuberculosis in mainland China from 1998 to 2017: the effect of DOTS strategy and further control. Theor Biol Med Model. 2020;17(1):6.","journal-title":"Theor Biol Med Model"},{"issue":"11","key":"7465_CR34","doi-asserted-by":"publisher","first-page":"e806","DOI":"10.1016\/S2214-109X(16)30199-1","volume":"4","author":"RMGJ Houben","year":"2016","unstructured":"Houben RMGJ, Menzies NA, Sumner T, Huynh GH, Arinaminpathy N, Goldhaber-Fiebert JD, et al. Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. Lancet Glob Health. 2016;4(11):e806\u201315.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"7465_CR35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40249-020-00682-7","volume":"9","author":"B-Y Li","year":"2020","unstructured":"Li B-Y, Shi W-P, Zhou C-M, Zhao Q, Diwan VK, Zheng X-B, et al. Rising challenge of multidrug-resistant tuberculosis in China: a predictive study using Markov modeling. Infect Dis Poverty. 2020;9(1):65.","journal-title":"Infect Dis Poverty"},{"key":"7465_CR36","first-page":"274","volume":"5","author":"C Liu","year":"2020","unstructured":"Liu C, Yan X. Advances in clinical application research of mycobacterium vaccae on treatment of tuberculosis. Electron J Emerg Infect Dis. 2020;5:274\u20136.","journal-title":"Electron J Emerg Infect Dis"},{"key":"7465_CR37","unstructured":"Organization WH. Global tuberculosis report 2019. World Health Organization; 2019. https:\/\/apps.who.int\/iris\/handle\/10665\/329368. Accessed 3 Apr 2022."},{"issue":"11","key":"7465_CR38","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1080\/21645515.2016.1205769","volume":"12","author":"RC Harris","year":"2016","unstructured":"Harris RC, Sumner T, Knight GM, White RG. Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines. Hum Vaccin Immunother. 2016;12(11):2813\u201332.","journal-title":"Hum Vaccin Immunother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07465-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07465-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07465-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T13:04:33Z","timestamp":1653311073000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07465-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7465"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07465-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]},"assertion":[{"value":"23 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not use any personal information and animals were not involved. In other words, the data used in this study were anonymous before its use. And there were no administrative permissions required to access the raw datasets used in our study. Therefore, no ethical approval was necessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"488"}}